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Alzheimer’s  disease  (AD)  is  the  largest
cause of dementia, affecting 35.6 million peo-
ple in 2010. Amyloid precursor protein, prese-
nilin 1 and presenilin 2 mutations are known
to  cause  familial  early-onset  AD,  whereas
apolipoprotein E (APOE) ʵ4 is a susceptibility
gene for late-onset AD. The genes for phos-
phatidylinositol-binding clathrin assembly pro-
tein, clusterin and complement receptor 1 have
recently been described by genome-wide asso-
ciation studies as potential risk factors for late-
onset  AD.  Also,  a  genome  association  study
using  single  neucleotide  polymorphisms  has
identified an association of neuronal sortilin
related receptor and late-onset AD. Gene test-
ing, and also predictive gene testing, may be of
benefit  in  suspected  familial  early-onset  AD
however it adds little to the diagnosis of late-
onset AD and does not alter the treatment. We
do not recommend APOE ʵ4 genotyping. 
Introduction
Alzheimer’s Disease International estimates
that  in  2010  35.6  million  people  will  have
dementia.1 Alzheimer’s  disease  (AD),  a  dis-
ease first described by Alois Alzheimer in 1906,
is the largest cause of dementia.2,3 AD typical-
ly affects those aged over 65 years (late-onset
AD) but can also affect those younger than 65
years (early-onset AD).4,5 AD is an insidious
neurodegenerative  disease,  beginning  with
self-reported short-term memory problems and
progressing until total loss of cognitive func-
tion and death.2 Current AD medications have
a minor symptomatic effect and do not prevent
its progression. The brains of AD patients are
characterized by extracellular plaques of amy-
loid-beta (Aʲ) and intracellular neurofibrillary
tangles  containing  hyperphosphorylated  tau
protein.6 The process by which these plaques
and tangles cause AD is not perfectly under-
stood, however three genes were identified to
be involved in familial early-onset AD in the
mid-1990s, namely amyloid precursor protein
(APP) and the presenilins (PSEN1 and PSEN2)
(Table  1).6,7 Mutations  in  these  genes  only
account  for  a  very  small  percentage  of  AD
patients,4 and the search for other potential
causes of AD continued. The apolipoprotein E
(APOE)  ʵ4  allele  has  been  identified  as  a
major risk factor for the development of late-
onset AD, but not all those who possess the
allele develop AD and not all who have AD pos-
sess the allele.4 A genome association study
using  single  neucleotide  polymorphisms
(SNPs) has identified an association of neu-
ronal  sortilin  related  receptor  (SORL1)  and
late  onset  AD.8 More  recently  genome-wide
association  studies  (GWAS)  have  identified
some  novel  genes  associated  with  AD:  clus-
terin  (CLU),  complement  receptor  1  (CR1),
and  phosphatidylinositol-binding  clathrin
assembly protein (PICALM).3,6,7 This paper will
examine the clinical utility of genetic testing
in AD in light of recent discoveries. 
Familial early-onset Alzheimer’s
disease
Familial early-onset AD is a very rare dis-
ease  which  occurs  when  a  highly  penetrant
gene mutation is inherited in an autosomal
dominant pattern. As mentioned above, muta-
tions in APP, PSEN1, and PSEN2 have been
identified  as  causes  of  familial  early-onset
AD.4 Genetic testing may be of benefit in this
situation as the identification of the specific
mutation in affected family members will con-
firm the diagnosis of familial early onset AD.4
A similar, and well established, example of an
autosomal dominant neurodegenerative disor-
der is Huntington’s Disease (HD). Research
conducted with HD families is the basis for
many  of  the  recommendations  regarding
genetic testing for autosomal dominant neu-
rodegenerative disorders.4 As with HD, predic-
tive gene testing may be requested by unaffect-
ed family members in a familial early-onset AD
as knowledge of carrier status may have impli-
cations for reproduction.4 Furthermore, preim-
plantation genetic diagnosis may be an option
if a known carrier would like to ensure they do
not pass the mutation onto future offspring.4
At least one instance of this has been reported
in the literature, with a healthy child born.10
Late-onset Alzheimer’s disease
Late-onset AD is the most common form of
AD,  and  is  usually  sporadic.  However,  as
already  mentioned,  some  alleles  have  been
identified to increase the risk of developing
late-onset AD. APOE ʵ4 is a well-established
risk  factor  for  AD,  and  is  associated  with  a
four-fold  risk  of  developing  the  disease.4-6,11
Since 2007 a number of GWAS have been per-
formed confirming that APOE ʵ4 is the most
significant  gene  associated  with  late-onset
AD.12-14 Other  identified  genes  have  only  a
small  effect  on  the  risk  of  developing  AD.
SORL1 has been associated with late-onset AD
through using SNPs, and PICALM, CLU, and
CR1 have recently been identified by GWAS as
novel risk factor loci.3,6-8,13,14 GRB2-associated
binding protein 2(GAB2), bridging integrator 1
(BIN1),  exocyst  component  3-like  2
(EXOC3L2)  and  methylenetetrahydrofolate
dehydrogenase  (NAPD+ dependent)  1-like
(MTHFD1L) have been identified as associat-
ed with the development of AD, but have been
replicated with mixed results.15-17 Other possi-
ble AD genes can be found online (www.mol-
gen.ua.ac.be/ADMutations and www.alzgene. org).
Unlike familial early-onset AD, the presence
of these genes does cause AD, but are rather
susceptibility genes. Whilst genetic testing can
readily  identify  the  presence  or  absence  of
these susceptibility genes, this is of little clin-
ical  or  diagnostic  benefit.4,18 A  patient  may
carry the APOE ʵ4 allele and not develop AD, or
may develop AD without the APOE ʵ4 allele.19
Recommendations for gene testing
in Alzheimer’s disease 
Diagnosis of Alzheimer’s disease
The  diagnosis  of  AD  can  be  difficult  and
clinical expertise is required to distinguish it
from  other  neurodegenerative  disorders.
Appropriate  clinical  guidelines,  modified  in
the modern era and including clinical history,
neurological examination, imaging in the form
of MRI and PET, and genetic testing in appro-
priate  individuals,  should  be  followed.20,21
Currently, the diagnosis of AD should not rely
solely on genetic testing, but should rather be
built from a number of resources. 
Familial early-onset Alzheimer’s disease
A positive family history of early-onset AD
with an autosomal dominant inheritance pat-
tern  is  strongly  suggestive  of  familial  early-
onset  AD.  A  patient  with  suspected  familial
early onset AD should be referred to a clinician
with an interest in familial dementia and expe-
rience in genetic neurodegenerative disorders
to confirm the diagnosis.4 Genetic testing may
be carried out, with the patient’s permission,
to determine if there are mutations in APP,
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[Neurology International 2011; 3:e1] [page 1]PSEN1,  or  PSEN2  which  would  confirm  the
diagnosis  of  familial  early-onset  AD.4,9 If  a
demented person has a PSEN1 mutation and
has a MRI scan that is supportive, then the
diagnosis  is  AD.  DNA  banking,  for  future
analysis, should be provided as an option for
those who do not currently want a test or those
who may lack a known mutation.4
Predictive  gene  testing  for  mutations  in
APP, PSEN1, or PSEN2 in healthy adults should
be conducted in a setting of adequate genetic
counseling  and  confidentiality.  This  should
consist of counseling regarding the purpose of
performing testing, the meaning of positive or
negative results, the implication of results for
the  patient  and  their  family,  alternative
options, the benefits and risks, and reassur-
ance that care will not be withdrawn as a result
of not undergoing testing.4,9Despite the lack of
a cure for familial early-onset AD, there are
some benefits to undergoing predictive gene
testing.  These  include  life-planning  (e.g.
whether or not to reproduce) and social plan-
ning (e.g. financial and social support).4,9 The
risks of predictive gene testing include depres-
sion, disruption to family and breach of confi-
dentiality, which could lead to social stigmati-
zation, job or health insurance loss in those
found to have the mutation.9 For those without
a mutation the risks include depression and
survivor’s guilt.9 Genetic information is both
inherently individual and also shared by a fam-
ily;  therefore  there  may  be  some  dilemmas
when one individual would like to undergo pre-
dictive  gene  testing  when  their  parent  or
monozygotic twin does not wish to know their
genetic status.4,9 It is best that an agreement
be reached through adequate counseling; how-
ever if agreement cannot be reached then pre-
dictive gene testing should be carried out pro-
vided the parent or twin has time to protect
against inadvertently learning the outcome.9
Late-onset Alzheimer’s disease
For  patients  with  sporadic  late-onset  AD
genetic testing for APOE ʵ4, SORL1, CLU, CR1,
or PICALM is not recommended as it does not
provide  clinically  useful  information.  These
risk factor genes do not improve the sensitivi-
ty of specificity of the diagnosis, nor do they
alter the treatment.4,18 Predictive gene testing
for these risk factor genes is also not recom-
mended as there is currently no potential for
prevention or early-intervention. Knowledge of
APOE ʵ4 status in adults with a parent with
Alzheimer’s disease did not result in signifi-
cant short-term psychological distress accord-
ing to the REVEAL study conducted by Green
and colleagues.22 However research conducted
by Chilibeck and colleagues demonstrates that
this knowledge is assimilated into pre-existing
beliefs about family susceptibility and the com-
plexity  of  disease  causation.23 Furthermore,
knowledge of the absence of APOE ʵ4 did not
dissuade some from the belief that they will
develop AD.23 Patients already have their own
beliefs of their susceptibility and knowledge of
genetic risk, delivered with counseling, does
not  profoundly  change  their  beliefs.23 This
illustrates that there is little benefit to knowl-
edge of APOE ʵ4. After all, a lack of risk factor
genes holds no guarantee that the individual
will not develop late-onset AD and conversely
the presence holds no guarantee the individual
will develop the disease. 
Education, counseling and support
As always, genetic testing should be carried
out in a setting of confidentiality, education,
counseling, and support from a multidiscipli-
nary team with expertise in genetic neurode-
generative disorders.4,9 The patient and their
family should understand the risks and bene-
fits, their alternative options and the implica-
tions of the results.4,9 In the instance that the
patient is demented to the extent that they are
unable  to  give  informed  consent  and  family
members  are  not  united  in  the  decision  to
undergo genetic testing, then it should not be
performed  until  a  consensus  is  reached.
Genetic  counseling,  as  part  of  multidiscipli-
nary care, should be provided to assist resolu-
tion.  
Laboratory accreditation and DNA result
disclosure
DNA testing for patients with suspected AD
should always take place in an appropriately
accredited laboratory. Whilst the accreditation
requirements vary in each nation, the testing
should be carried out in a reputable laboratory
with quality controls in place to ensure accura-
cy.4,9,24 The US NIH Genetic Testing Registry,
which is expected to become operational in the
near future, will address the utility and avail-
ability of genetic tests and make this informa-
tion publicly available, however it will be rely-
ing on genetic testing providers to voluntarily
submit information.25 The success of this reg-
istry  will  become  evident  in  time.  Direct  to
consumer (DTC) genetic testing is not recom-
mended for either familial AD or sporadic AD
gene testing. As a result of a report from the
US Government Accountability off ice, the US
Food  and  Drug  Administration  has  recently
notified  a  number  of  DTC  service  providers
that  their  products  meet  the  definition  of  a
medical  device  based  on  the  manufacturer’s
claims about test results, and therefore now
need  to  be  proven  to  be  safe,  accurate  and
effective.26,27 Up to now these tests had been
unregulated and alarmingly one manufacturer
had  planned  to  make  their  test  available
through a pharmacy chain.26 The risks of DTC
genetic  testing  lie  in  decision  making  as  a
result of the genetic test.9,26 Also there have
been instances of consumers receiving results
belonging to someone else.28 This highlights
the  importance  of  laboratory  regulation  and
genetic  counseling  as  part  of  the  testing
process. To ensure confidentiality, the results
of genetic testing should go directly to the cli-
nician who requested the test.4 They can then
be  delivered  to  the  patient  and  their  carer
under strict confidence, with assistance from
genetic counselors.4,9 These counselors should
continue follow-up with the patient to reduce
the risk of adverse reactions, such as psychi-
atric  hospitalization  and  suicide  attempts.4
This  method  as  has  been  successful  with
Huntington’s disease.29
Conclusions
Genetic testing has a role in the diagnosis of
familial early-onset AD, however it adds little
to the diagnosis of sporadic AD. The use of pre-
dictive gene testing for people at risk of famil-
ial early-onset AD may be beneficial, however
it is not recommended for risk-factor genes,
including APOE ʵ4, particularly as there is no
known preventative or curative measure avail-
able. Any genetic testing should always be con-
ducted in a setting of adequate genetic coun-
seling in a regulated and reputable laboratory.
Confidentiality  of  results  should  always  be
assured to the patient.  
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